1-6 of 6
Anusha Vallurupalli
Close
Sort by
Journal Articles

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Uri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, Soyoung Kim, Amy Moskop, Farrukh T. Awan, Umar Farooq, Siddhartha Ganguly, Peiman Hematti, Michael D. Jain, Partow Kebriaei, Frederick L. Locke, Elena Mead, Taiga Nishihori, Amanda L. Olson, Martina Pennisi, Miguel-Angel Perales, Praveen Ramakrishnan Geethakumari, Roni Shouval, Elizabeth J. Shpall, Margarida Magalhaes Magalhaes-Silverman, Christopher Strouse, Cameron J. Turtle, Anusha Vallurupalli, Kitsada Wudhikam, Marcelo C. Pasquini, Sairah Ahmed, Mohamed Sorror
Journal: Blood
Blood (2022) 140 (Supplement 1): 4636–4638.
https://doi.org/10.1182/blood-2022-169452
Published: 2022
Journal Articles

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

Jeremy S. Abramson, Amy S. Ruppert, Sharmila Giri, Ann Hudson, Eric D. Hsi, Richard F. Little, Steven D. Gore, Anusha Vallurupalli, Daniel J Landsburg, Brad S. Kahl, Jonathan W. Friedberg, Nancy L. Bartlett, John P. Leonard
Journal: Blood
Blood (2021) 138 (Supplement 1): 523.
https://doi.org/10.1182/blood-2021-151266
Published: 2021
Journal Articles

Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma

Tycel J. Phillips, MD, Adam J Olszewski, MD, Javier Munoz, MD, Tae Min Kim, MD PhD, Dok Hyun Yoon, Richard Greil, MD, Jason Westin, MD, Ulrich Jaeger, Miguel Canales, Cindy Chen, Betsy Althaus, Carol O'Hear, Raluca Negricea, Yuying Xie, Ronald McCord, Enkhtsetseg Purev, Anusha Vallurupalli
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-136295
Published: 2020
Journal Articles

Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study

Pierluigi Porcu, MD, Brad M. Haverkos, MDMPH,MS, Onder Alpdogan, MD, Marcelo Capra, MD PhD, Tatyana A. Feldman, MD, Elizabeth Brem, MD, Anusha Vallurupalli, MD, Jonathan E. Brammer, MD, Ana Schriefer, Juliana Pereira, MD PhD, Anil Tulpule, MD, Stefan K. Barta, MD MRCP, MS, Locke J. Bryan, MD, Richard Trauger, Sebastian Obrzut, John Gutheil, MD, Afton Katkov, MSc, Robert McRae, Ivor Royston, MD, Douglas V. Faller, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 465.
https://doi.org/10.1182/blood-2019-132004
Published: 2019
Journal Articles

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Patrick J. Stiff, MD, Emad Ibrahim, MBBCh, MD, Anusha Vallurupalli, MBBS, Elizabeth H. Cull, MD, Damian J. Green, MD, Kate Oliver, BS, Jarrod Longcor
Journal: Blood
Blood (2019) 134 (Supplement_1): 144.
https://doi.org/10.1182/blood-2019-131014
Published: 2019
Journal Articles

CDC37 As a Novel Target for the Treatment of NPM1-ALK Expressing Anaplastic Large Cell Lymphomas

Sudhakiranmayi Kuravi, M.S., Elizabeth Parrott, M.A., Siddhartha Ganguly, MD, Anusha Vallurupalli, MD, Yogenthiran Saunthararajah, MD, Brian S Blagg, PhD, Jensen Roy, MD, Joseph P. McGuirk, DO, Ramesh Balusu, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2758.
https://doi.org/10.1182/blood.V130.Suppl_1.2758.2758
Published: 2017